TISSUE POLYPEPTIDE SPECIFIC ANTIGEN (TPS) AS A TUMOR MARKER FOR GYNECOLOGIC MALIGNANCIES : A COMPARATIVE STUDY WITH TISSUE POLYPEPTIDE ANTIGEN (TPA), CANCER ANTIGEN 125 (CA125) AND SQUAMOUS CELL CARCINOMA-ASSOCIATED ANTIGEN (SCC)
1957年共同研究者により各種腫瘍組織混合抽出液より精製されたtissue polypeptide antigen (TPA)はその後cytokeratins 8, 18, 19との交差反応が見られ,一種の細胞構築蛋白であることが判明している。最近Bjurk・lundはTPAをマウスに免疫しcytokeratinと交差しない単クローン抗体M3を得た。同抗体を使用して組み立てられたimmunoradiometrical assay (IRMA)を用いてspecific TPA (TPS)を各種婦人科癌患者血清にて測定し,従来のTPA, cancer antigen 125 (CA 125)およびsquamous cell carcinoma-associated antigen (SCC)と比較し,その臨床的有用性と限界を検討した。A new immunoradiometrical assay (IRMA) for a tissue polypeptide specific antigen (TPS) has recently been established using a monoclonal antibody (M 3) against purified tissue polypeptide antigen (TPA). With the use of this IRMA, we measured serum TPS levels in 68 patients with benign gynecologic diseases and in 71 patients with gynecologic malignancies before treatment. Eleven gynecological cancer patients who showed the positivity for TPS before the treatment were followed up by monitoring the serum TPS levels. Tissue polypeptide antigen (TPA), cancer antigen 125 (CA 125) or squamous cell carcinoma-associated antigen (SCC) were also measured in these patients. The present study first described the clinical usefulness and weakness of TPS as a tumor marker for gynecologic malignancies by making a comparison with TPA, CA 125 or SCC
